Opportunities and Challenges for Nanotherapeutics for the Aging Population

Nicholas J. Hunt; Nicholas J. Hunt; Nicholas J. Hunt; Nicholas J. Hunt; Peter A. G. McCourt; Peter A. G. McCourt; Zdenka Kuncic; Zdenka Kuncic; David G. Le Couteur; David G. Le Couteur; David G. Le Couteur; Victoria C. Cogger; Victoria C. Cogger; Victoria C. Cogger

doi:10.3389/fnano.2022.832524

Frontiers in Nanotechnology (Jan 2022)

Opportunities and Challenges for Nanotherapeutics for the Aging Population

Nicholas J. Hunt,
Nicholas J. Hunt,
Nicholas J. Hunt,
Nicholas J. Hunt,
Peter A. G. McCourt,
Peter A. G. McCourt,
Zdenka Kuncic,
Zdenka Kuncic,
David G. Le Couteur,
David G. Le Couteur,
David G. Le Couteur,
Victoria C. Cogger,
Victoria C. Cogger,
Victoria C. Cogger

Affiliations

Nicholas J. Hunt: ANZAC Research Institute, Ageing and Alzheimer’s Institute and Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW, Australia
Nicholas J. Hunt: Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
Nicholas J. Hunt: Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
Nicholas J. Hunt: Sydney Nano Institute, The University of Sydney, Camperdown, NSW, Australia
Peter A. G. McCourt: Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
Peter A. G. McCourt: Department of Medical Biology, University of Tromsø—The Arctic University of Norway, Tromsø, Norway
Zdenka Kuncic: Sydney Nano Institute, The University of Sydney, Camperdown, NSW, Australia
Zdenka Kuncic: School of Physics, The University of Sydney, Sydney, NSW, Australia
David G. Le Couteur: ANZAC Research Institute, Ageing and Alzheimer’s Institute and Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW, Australia
David G. Le Couteur: Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
David G. Le Couteur: Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
Victoria C. Cogger: ANZAC Research Institute, Ageing and Alzheimer’s Institute and Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW, Australia
Victoria C. Cogger: Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
Victoria C. Cogger: Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia

DOI: https://doi.org/10.3389/fnano.2022.832524
Journal volume & issue: Vol. 4

Abstract

Read online

Nanotherapeutics utilize the properties of nanomaterials to alter the pharmacology of the drugs and therapies being transported, leading to changes in their biological disposition (absorption, distribution, cellular uptake, metabolism and elimination) and ultimately, their pharmacological effect. This provides an opportunity to optimize the pharmacology of drugs, particularly for those that are dependent on hepatic action. Old age is associated with changes in many pharmacokinetic processes which tend to impair drug efficacy and increase risk of toxicity. While these age-related changes are drug-specific they could be directly addressed using nanotechnology and precision targeting. The benefits of nanotherapeutics needs to be balanced against toxicity, with future use in humans dependent upon the gathering of information about the clearance and long-term safety of nanomaterials.

Published in Frontiers in Nanotechnology

ISSN: 2673-3013 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Technology: Chemical technology
Website: https://www.frontiersin.org/journals/nanotechnology#

About the journal

Abstract

Keywords